Vanqua Bio will initiate clinical development of VQ-101 — a small molecule capable of penetrating the brain — in the first quarter of 2024, the company announced. The clinical testing will involve both healthy volunteers and individuals with Parkinson’s disease associated with mutations in the GBA gene.
Low-dose fosgonimeton (ATH-1017), an investigational small molecule, may have cognitive benefits for people with Parkinson’s disease-related dementia or dementia with Lewy bodies, according to recent data from a clinical trial. The small exploratory Phase 2 study, called SHAPE (NCT04831281), tested the safety and efficacy of fosgonimeton given once…
The U.S. Food and Drug Administration (FDA) has cleared NeuroOne’s OneRF Ablation System, a brain electrode-guided tool employed in neurosurgical procedures, including those for Parkinson’s disease, to capture electrical activity and selectively destroy nervous tissue within controlled temperature settings. The request was submitted through a 510(k) application, which…
People with Parkinson’s disease and their caregivers need more timely information on what palliative care services are available and how to access them, along with more of such services, according to a review of published studies. Palliative care refers to specialized medical care for people living with a serious…
Amneal Pharmaceuticals and Bial have entered into a licensing agreement giving Amneal exclusive rights to market and distribute Ongentys (opicapone) in the U.S. as an add-on treatment for people with Parkinson’s disease. Owned by Bial, Ongentys was approved by the U.S. Food and…
Researchers have developed a way to generate a family of nerve cells implicated in Parkinson’s disease in the lab using human stem cells, according to newly published research. These cells, found in a brain region called the locus coeruleus (LC), produce a signaling chemical called norepinephrine, or NE. While these…
Neurocrine Biosciences is opening two Phase 1 clinical trials in healthy adults to test two oral candidate muscarinic receptor agonists intended to treat Parkinson’s disease and other neurological conditions. Both investigational therapies — called NBI-1117569 and NBI-1117567 — were developed by Sosei Heptares, which licensed…
A neurologist and movement disorders specialist at the University of California, Los Angeles (UCLA), is working to develop a way to help Parkinson’s disease researchers better assess and recruit Black patients into clinical studies. If successful, the tool planned by Jennifer Adrissi could be adapted for use…
Members of the Support Group for Black Patients with Parkinson’s Disease took part in the Parkinson Council’s Walk to Stamp Out Parkinson’s event in November and raised more than $3,400, helping the Council to come within 70% of its $400,000 fundraising goal. The support group, which was launched in…
Alterity Therapeutics‘ ATH434 improved motor performance and overall function in non-human primates with induced Parkinson’s disease, according to data presented at the recent Future of Parkinson’s Disease Conference 2023. The investigational therapy is currently undergoing evaluation in an open-label biomarker study called ATH434-202 (NCT05864365), which has…
Get regular updates to your inbox.
